Importantly (and consistent with our previous results from the single-tumor experiments), CD8+ T cells were essential for greater survival of the treated groups; thus, in mice bearing bilateral MC38 (Figure 4A) or CT26 (Figure 4C) tumors, the benefits of the combination treatment on survival are completely abrogated after depletion of CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.